BDKRB1 and central nervous system cancer: SSR240612 (bradykinin 1 receptor antagonist) and HOE-140 (bradykinin 2 receptor antagonist) favor the death of glioma cells via apoptosis and necrosis [39,139], and treatment with BKM-570 (bradykinin antagonist) and temozolomide significantly increases the antitumor action of temozolomide against glioma cells [140].